Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non-small-cell lung cancer (EURTAC): a multicentre, open-label, randomised phase 3 trialRafael Rosell, Ana Drozdowskyj, Filippo de Marinis et al.|The Lancet Oncology|2012Cited by 5.5k
PTEN: Multiple Functions in Human Malignant TumorsMichèle Milella, Ludovica Ciuffreda|Frontiers in Oncology|2015Cited by 460
MEK blockade converts AML differentiating response to retinoids into extensive apoptosisMichèle Milella, Michael Andreeff|Blood|2006Cited by 42
Real-World Data on Cabozantinib in Previously Treated Patients with Metastatic Renal Cell Carcinoma: Focus on Sequences and Prognostic FactorsMatteo Santoni, Nicola Battelli, Daniel Y.C. Heng et al.|Cancers|2019Cited by 31
Development of a nomogram for predicting pathological complete response in luminal breast cancer patients following neoadjuvant chemotherapyGiovanna Garufi, Emilio Bria, Luisa Carbognin et al.|Therapeutic Advances in Medical Oncology|2023Cited by 11